Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.

Bower K, Napier CE, Cole SL, Dagg RA, Lau LM, Duncan EL, Moy EL, Reddel RR.

PLoS One. 2012;7(11):e50062. doi: 10.1371/journal.pone.0050062. Epub 2012 Nov 20.

2.

Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.

Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker AK; ALT Starr Cancer Consortium.

PLoS Genet. 2012;8(7):e1002772. Epub 2012 Jul 19.

3.

ATRX represses alternative lengthening of telomeres.

Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, Reddel RR.

Oncotarget. 2015 Jun 30;6(18):16543-58.

4.

Altered telomeres in tumors with ATRX and DAXX mutations.

Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK.

Science. 2011 Jul 22;333(6041):425. doi: 10.1126/science.1207313. Epub 2011 Jun 30.

5.

Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids.

Perrem K, Bryan TM, Englezou A, Hackl T, Moy EL, Reddel RR.

Oncogene. 1999 Jun 3;18(22):3383-90.

6.

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A.

Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.

PMID:
24148618
7.

Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.

Tang M, Li Y, Zhang Y, Chen Y, Huang W, Wang D, Zaug AJ, Liu D, Zhao Y, Cech TR, Ma W, Songyang Z.

J Cell Sci. 2015 Jan 15;128(2):331-41. doi: 10.1242/jcs.159467. Epub 2014 Nov 21.

8.

Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.

Liau JY, Tsai JH, Yang CY, Lee JC, Liang CW, Hsu HH, Jeng YM.

Hum Pathol. 2015 Sep;46(9):1360-6. doi: 10.1016/j.humpath.2015.05.019. Epub 2015 Jun 5.

PMID:
26190196
9.

Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.

Liau JY, Tsai JH, Jeng YM, Lee JC, Hsu HH, Yang CY.

Am J Surg Pathol. 2015 Feb;39(2):236-44. doi: 10.1097/PAS.0000000000000324.

PMID:
25229770
10.

Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.

Lee JC, Jeng YM, Liau JY, Tsai JH, Hsu HH, Yang CY.

Mod Pathol. 2015 Aug;28(8):1064-73. doi: 10.1038/modpathol.2015.67. Epub 2015 May 29.

11.

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Liau JY, Lee JC, Tsai JH, Yang CY, Liu TL, Ke ZL, Hsu HH, Jeng YM.

Mod Pathol. 2015 Dec;28(12):1545-54. doi: 10.1038/modpathol.2015.114. Epub 2015 Oct 2.

PMID:
26428317
12.

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.

Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, Taylor S, Higgs DR, Gibbons RJ.

Nat Commun. 2015 Jul 6;6:7538. doi: 10.1038/ncomms8538.

13.

Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.

Kim HS, Lee HS, Nam KH, Choi J, Kim WH.

Anticancer Res. 2015 Jun;35(6):3501-10.

PMID:
26026117
14.

Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.

Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR.

Mol Cell Biol. 2001 Jun;21(12):3862-75.

15.

Clinical features of ATRX or DAXX mutated neuroblastoma.

Kurihara S, Hiyama E, Onitake Y, Yamaoka E, Hiyama K.

J Pediatr Surg. 2014 Dec;49(12):1835-8. doi: 10.1016/j.jpedsurg.2014.09.029. Epub 2014 Nov 14.

PMID:
25487495
16.
17.

Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin.

Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M, Arnoult N, LondoƱo-Vallejo A, Decottignies A.

Nucleic Acids Res. 2014 Apr;42(7):4391-405. doi: 10.1093/nar/gku114. Epub 2014 Feb 5.

18.

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ, Hruban RH, Matsukuma KE.

Mod Pathol. 2012 Jul;25(7):1033-9. doi: 10.1038/modpathol.2012.53. Epub 2012 May 11.

19.

Loss of ATRX Suppresses Resolution of Telomere Cohesion to Control Recombination in ALT Cancer Cells.

Ramamoorthy M, Smith S.

Cancer Cell. 2015 Sep 14;28(3):357-69. doi: 10.1016/j.ccell.2015.08.003.

20.

The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit.

Bryan TM, Marusic L, Bacchetti S, Namba M, Reddel RR.

Hum Mol Genet. 1997 Jun;6(6):921-6.

Items per page

Supplemental Content

Write to the Help Desk